Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1826]

Dasatinib vs imatinib for paediatric Ph ALL

Dr Ching-Hon Pui - St Jude's Children's Research Hospital, Memphis, USA

Dasatinib vs imatinib for paediatric Ph ALL ( Dr Ching-Hon Pui - St Jude's Children's Research Hospital, Memphis, USA )

Study of quadruple combination for induction resistant myeloma reveals novel...

Dr Yael Cohen - Tel Aviv Sourasky Medical Center, Tel Aviv, Israel

Study of quadruple combination for induction resistant myeloma reveals novel immune checkpoints ( Dr Yael Cohen - Tel Aviv Sourasky Medical Center, Tel Aviv, Israel )

KRd vs KTd followed by carfilzomib maintenance in newly diagnosed MM

Prof Heinz Ludwig - Wilhelmeninen Cancer Research Institute, Vienna, Austria

KRd vs KTd followed by carfilzomib maintenance in newly diagnosed MM ( Prof Heinz Ludwig - Wilhelmeninen Cancer Research Institute, Vienna, Austria )

Azacitidine plus nivolumab in older adults with AML or MDS

Prof Annette Hay - Queen's University, Ontario, Canada

Azacitidine plus nivolumab in older adults with AML or MDS ( Prof Annette Hay - Queen's University, Ontario, Canada )

Venetoclax chemo combo active and well-tolerated in children with r/r AML

Dr Seth Karol - St. Jude Children’s Research Hospital, Memphis, USA

Venetoclax chemo combo active and well-tolerated in children with r/r AML ( Dr Seth Karol - St. Jude Children’s Research Hospital, Memphis, USA )

Laser therapy for vulvo-vaginal atrophy / genito-urinary syndrome of menopause...

Prof Deborah Fenlon - Swansea University, Swansea, UK

Laser therapy for vulvo-vaginal atrophy / genito-urinary syndrome of menopause in breast cancer survivors ( Prof Deborah Fenlon - Swansea University, Swansea, UK )

Depth of response to daratumumab, lenalidomide, bortezomib, and dexamethasone...

Prof Peter Voorhees - Levine Cancer Institute, Charlotte, USA

Depth of response to daratumumab, lenalidomide, bortezomib, and dexamethasone improves over time in transplant-eligible newly diagnosed multiple myeloma ( Prof Peter Voorhees - Levine Cancer Institute, Charlotte, USA )

Blinatumomab vs chemotherapy as post-reinduction therapy in HR/IR first relapse...

Dr Patrick Brown - Johns Hopkins University, Baltimore, USA

Blinatumomab vs chemotherapy as post-reinduction therapy in HR/IR first relapse of B-ALL in children and adolescents ( Dr Patrick Brown - Johns Hopkins University, Baltimore, USA )

Maintenance therapy with CC-486 for acute myeloid leukaemia

Prof Andrew Wei - Monash University, Melbourne, Australia

Maintenance therapy with CC-486 for acute myeloid leukaemia ( Prof Andrew Wei - Monash University, Melbourne, Australia )

Daratumuab, carfilzomib and dexamethasone increases survival in patients with...

Dr Saad Usmani - Levine Cancer Institute, Charlotte, USA

$Daratumuab, carfilzomib and dexamethasone increases survival in patients with relapsed/refractory multiple myeloma ( Dr Saad Usmani - Levine Cancer Institute, Charlotte, USA )$

QUAZAR AML-001: Evaluating CC-486 as a maintenance therapy for older patients...

Prof Andrew Wei - Monash University, Melbourne, Australia

QUAZAR AML-001: Evaluating CC-486 as a maintenance therapy for older patients with acute myeloid leukaemia in first remission ( Prof Andrew Wei - Monash University, Melbourne, Australia )

Blinatumomab demonstrates superior efficacy compared to chemotherapy in...

Dr Patrick Brown - Johns Hopkins University, Baltimore, USA

Blinatumomab demonstrates superior efficacy compared to chemotherapy in children and young adults with relapsed B-ALL ( Dr Patrick Brown - Johns Hopkins University, Baltimore, USA )

More from ecancer